Literature DB >> 15951919

Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report.

Ismail Hanta, Mesut Demir, Onur Akpinar, Ali Kocabas, Suleyman Ozbek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15951919     DOI： 10.1007/s10067-005-1090-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  10 in total

1.  Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension.

Authors:  Roberto Littera; Giorgio La Nasa; Giorgio Derchi; Maria D Cappellini; Christy Y P Chang; Licinio Contu
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

2.  Primary and secondary pulmonary hypertension in systemic lupus erythematosus.

Authors:  T L Pan; J Thumboo; M L Boey
Journal:  Lupus       Date:  2000       Impact factor: 2.911

3.  Successful treatment of systemic lupus erythematosus and pulmonary hypertension with intravenous prostaglandin I2 followed by its oral analogue.

Authors:  H Ooiwa; T Miyazawa; Y Yamanishi; K Hiyama; S Ishioka; M Yamakido
Journal:  Intern Med       Date:  2000-04       Impact factor: 1.271

4.  Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.

Authors:  D Abrams; I Schulze-Neick; A G Magee
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

5.  Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension.

Authors:  H Wilkens; A Guth; J König; N Forestier; B Cremers; B Hennen; M Böhm; G W Sybrecht
Journal:  Circulation       Date:  2001-09-11       Impact factor: 29.690

6.  Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function.

Authors:  J M Pearl; S A Wellmann; J L McNamara; J P Lombardi; C J Wagner; J L Raake; D P Nelson
Journal:  Ann Thorac Surg       Date:  1999-11       Impact factor: 4.330

7.  Sildenafil for primary and secondary pulmonary hypertension.

Authors:  Hiroshi Watanabe; Kyoichi Ohashi; Kazuhiko Takeuchi; Kazuhiro Yamashita; Taku Yokoyama; Quang-Kim Tran; Hiroshi Satoh; Hajime Terada; Hiroyuki Ohashi; Hideharu Hayashi
Journal:  Clin Pharmacol Ther       Date:  2002-05       Impact factor: 6.875

8.  Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy.

Authors:  J Molina; E Lucero; S Luluaga; V Bellomio; A Spindler; A Berman
Journal:  Lupus       Date:  2003       Impact factor: 2.911

9.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.

Authors:  Hossein Ardeschir Ghofrani; Ralph Wiedemann; Frank Rose; Ralph T Schermuly; Horst Olschewski; Norbert Weissmann; Andreas Gunther; Dieter Walmrath; Werner Seeger; Friedrich Grimminger
Journal:  Lancet       Date:  2002-09-21       Impact factor: 79.321

Review 10.  Management of pulmonary hypertension resulting from interstitial lung disease.

Authors:  Shelley Shapiro
Journal:  Curr Opin Pulm Med       Date:  2003-09       Impact factor: 3.155
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.